[Results of treatment with intravenous amantadine sulfate (PK-Merz) patients with chronic disorders of consciousness].
E A KondratievaS A KondratevA A DenisovaN E IvanovaA N KondratievPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2021)
The article presents literature review of the recent publications devoted to the drugs with dopaminergic, antiglutamatergic and GABA-ergic effects in the treatment of patients with vegetative state/areactive wakefulness syndrome (VS/AWS). The authors analyzed their own results of the effects of intravenous form of amantadine sulfate (PK Merz) in 142 VS/AWS patients caused by different etiological factors. Depending on the dominant neurological symptoms, patients were divided into three main groups: areactive type of course (group 1 - 61 patients), predominance of primitive limbic reactions (group 2 - 35 patients) and predominance of extrapyramidal symptoms (group 3 - 46 patients). Therapy results were evaluated one month later by CRS-R scale, which showed that the most distinct positive dynamics was observed in group 3.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- low dose
- patient reported outcomes
- stem cells
- depressive symptoms
- mesenchymal stem cells
- patient reported
- physical activity
- blood brain barrier
- smoking cessation
- subarachnoid hemorrhage
- replacement therapy
- cell therapy